Samuel Barker
Director/Board Member chez LEXICON PHARMACEUTICALS, INC.
Fortune : 191 081 $ au 31/03/2024
Profil
Samuel L.
Barker was the founder of Clearview Projects, Inc. (founded in 2001) where he held the title of President & Chief Executive Officer from 2003 to 2004.
He currently holds the position of Independent Director at Lexicon Pharmaceuticals, Inc. since 2000, Independent Director at Cyclacel Pharmaceuticals, Inc. since 2014, Director at Canvas Energy LLC, and Trustee at The Cancer Institute of New Jersey.
His former positions include Director at AtheroGenics, Inc. from 2005 to 2009, Independent Director at Mallinckrodt Hospital Products, Inc. from 2006 to 2014, EVP-Worldwide Franchise Management & Strategy at Bristol Myers Squibb Co. in 1998, Executive Vice President at Worldwide Franchise Systems, Inc., and EVP-Worldwide Franchise Management & Strategy at United States Pharmaceutical Group LLC from 1992 to 1998.
Dr. Barker's education history includes an undergraduate degree from Henderson State University (Arkansas), a graduate degree from The University of Arkansas, and a doctorate degree from Purdue University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/03/2024 | 79 617 ( 0,03% ) | 191 081 $ | 31/03/2024 |
Postes actifs de Samuel Barker
| Sociétés | Poste | Début |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Director/Board Member | 01/01/2012 |
| CYCLACEL PHARMACEUTICALS, INC. | Director/Board Member | 11/09/2014 |
The Cancer Institute of New Jersey
 The Cancer Institute of New Jersey Hospital/Nursing ManagementHealth Services The Cancer Institute of New Jersey operates as a cancer centre. The firm offers cancer care for adults and children, providing access to the medicines and treatment options. It also offers clinical, patient education resources and support services. The company was founded in and is headquartered in New Brunswick, NJ. | Director/Board Member | - |
| Canvas Energy LLC | Director/Board Member | - |
Anciens postes connus de Samuel Barker
| Sociétés | Poste | Fin |
|---|---|---|
| CADENCE PHARMACEUTICALS, INC. | Director/Board Member | 19/03/2014 |
AtheroGenics, Inc.
 AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Director/Board Member | 01/04/2009 |
| Clearview Projects, Inc. | Chief Executive Officer | 01/01/2004 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/1999 |
United States Pharmaceutical Group LLC
 United States Pharmaceutical Group LLC Miscellaneous Commercial ServicesCommercial Services United States Pharmaceutical Group LLC provides healthcare support services. Its solutions include member enrollment, service and administration, comprehensive medical care services platform, benefit administration and offshore technical compliance (OTC) solutions, and employer group waiver plan. The company was founded on May 7, 2003 and is headquartered in Fort Lauderdale, FL. | President | 01/01/1998 |
Formation de Samuel Barker
| Henderson State University (Arkansas) | Undergraduate Degree |
| The University of Arkansas | Graduate Degree |
| Purdue University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
AtheroGenics, Inc.
AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
| Worldwide Franchise Systems, Inc. | |
Mallinckrodt Hospital Products, Inc.
 Mallinckrodt Hospital Products, Inc. Pharmaceuticals: MajorHealth Technology Mallinckrodt Hospital Products, Inc. operates as a biopharmaceutical company, which develops and commercializes proprietary product candidates used in the hospital setting. The firm offers OFIRMEV (acetaminophen injection), a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The company was founded by Theodore R. Schroeder, David A. Socks, and Cam L. Garner on May 26, 2004 and is headquartered in Hazelwood, MO. | Health Technology |
The Cancer Institute of New Jersey
The Cancer Institute of New Jersey Hospital/Nursing ManagementHealth Services The Cancer Institute of New Jersey operates as a cancer centre. The firm offers cancer care for adults and children, providing access to the medicines and treatment options. It also offers clinical, patient education resources and support services. The company was founded in and is headquartered in New Brunswick, NJ. | Health Services |
United States Pharmaceutical Group LLC
United States Pharmaceutical Group LLC Miscellaneous Commercial ServicesCommercial Services United States Pharmaceutical Group LLC provides healthcare support services. Its solutions include member enrollment, service and administration, comprehensive medical care services platform, benefit administration and offshore technical compliance (OTC) solutions, and employer group waiver plan. The company was founded on May 7, 2003 and is headquartered in Fort Lauderdale, FL. | Commercial Services |
| Canvas Energy LLC | |
| Clearview Projects, Inc. |
